RxDoctor Payments Data

Winnie Simmons, MD

General Practice · Maben, MSNPI 1568428647

Payments from drug & device makers

$1,349in general payments, 2019–2025

Across 73 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$362
  • Amgen$248
  • Novo Nordisk$199
  • Merck$133
  • Idorsia Pharmaceuticals US Inc$126
  • Xeris Pharmaceuticals, Inc.$50
  • plus $230 from 10 others

What the payments were for

  • Food & beverage$1,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,349 in reported general payments places this provider in the 75th percentile of 674 general practice providers in Mississippi.

See all general practice providers in Mississippi

Medicare billing

Part B allowed, 2024
$159,966
Medicare patients
375
Services billed
4,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$106,349
FarxigaDapagliflozin Propanediol130$98,327
JardianceEmpagliflozin76$60,187
EliquisApixaban74$46,753
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,204
LinzessLinaclotide31$18,912
TrulicityDulaglutide12$15,795
DapagliflozinDapagliflozin Propanediol26$14,672
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$12,542
JentaduetoLinagliptin/Metformin Hcl28$10,830
XareltoRivaroxaban17$8,748
SynjardyEmpagliflozin/Metformin Hcl14$8,408
Tresiba Flextouch U-100Insulin Degludec18$7,413
Tresiba Flextouch U-200Insulin Degludec13$7,390
MyrbetriqMirabegron19$6,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$199$106,34986 claims
AstraZenecaFarxiga$362$98,327130 claims
Boehringer IngelheimJardiance, Jentadueto, Synjardy, Synjardy Xr$34$85,330130 claims
PfizerEliquis, Premarin$44$49,70788 claims
Lilly USA, LLCTrulicity$23$15,79512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 674 general practice providers in Mississippi.

Other general practice in Maben

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →